Sodium benzoate is under clinical development by SyneuRx International (Taiwan) and currently in the Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Sodium benzoate’s likelihood of approval (LoA) and phase transition for Schizophrenia took place on 20 Jun 2022, which decreased the likelihood that the drug progresses to the next phase in its clinical pathway and decreased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Sodium benzoate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Sodium benzoate overview
Sodium benzoate (SND-1, SB-01, SR-01) is under development for the treatment of adolescent schizophrenia, refractory schizophrenia, add-on therapy in schizophrenia and dementia. It is administered through the oral route. It acts by targeting D-amino acid oxidase (DAAO).
SyneuRx International (Taiwan) overview
SyneuRx International (Taiwan) (SyneuRx International) is a bio-medical company that specializes in developing drugs for the treatment of central nervous system-related disorders. The company is headquartered in Taipei City, Taipei, Taiwan.
Quick View Sodium benzoate LOA Data
|Highest Development Stage|